Related Experiment Videos
[Testis cancer markers. Clinical use]
N Salesi1, B Di Cocco, F Alghisi
1I Facoltà di Medicina e Chirurgia, Divisione di Oncologia Medica, Azienda Ospedaliera S. Andrea, Rome, Italy.
Minerva Medica
|November 1, 2002
Summary
Testis tumors are rare, primarily affecting young men aged 15-35. This study examines the clinical use of serum markers like alfa-fetoprotein (AFP), human chorionic gonadotrophin (HCG), and lactate dehydrogenase (LDH) for diagnosis.
Area of Science:
- Oncology
- Urology
- Biochemistry
Context:
- Testis tumors are uncommon neoplasms, predominantly diagnosed in adolescents and young adults (15-35 years).
- Germ cell tumors constitute 90% of testicular malignancies; other origins include stromal cells or secondary metastases.
- Accurate diagnosis and monitoring of testis tumors are crucial for effective patient management.
Purpose:
- To review the current clinical applications of serum tumor markers in the management of testis tumors.
- To evaluate the utility of alfa-fetoprotein (AFP), human chorionic gonadotrophin (HCG), and lactate dehydrogenase (LDH) as diagnostic and prognostic indicators.
- To provide an overview of the role of these biomarkers in clinical practice.
Summary:
- Testis tumors are rare, with germ cell tumors being the most prevalent type.
- Serum markers including AFP, HCG, and LDH are vital tools in the clinical assessment of testicular neoplasms.
- The study examines the established and emerging roles of these biomarkers in diagnosis, prognosis, and treatment monitoring.
Impact:
- Enhanced understanding of serum marker utility in testis tumor management.
- Improved diagnostic accuracy and patient stratification through biomarker analysis.
- Potential for optimized treatment strategies and patient outcomes in testicular oncology.